These filings confirm the completion of the merger and the resulting insider ownership structure. Monitor future filings for potential insider transactions under the new equity plans and for any registration statements covering the shares issued to Fairmount.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $18.60entry
- T+1 · 20h ago +6.83%α +8.74% · $19.87
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple Form 3 filings were submitted by officers, directors, and a major stockholder of InMed Pharmaceuticals Inc. (now Mentari Therapeutics) following a merger effective November 6, 2026. The filings disclose insider equity holdings and a significant stake by Fairmount Healthcare Fund II L.P., which received over 10.5 million common shares, 4,013 shares of Series A Non-Voting Preferred Stock convertible into 4,013,000 common shares, and pre-funded warrants for 1,468,222 common shares in the merger. The filings are routine post-merger ownership disclosures and do not contain any material financial data or guidance.
Key Facts
- Effective November 6, 2026, InMed Pharmaceuticals Inc. completed a merger with Mentari Therapeutics Inc., with the issuer renamed Mentari Therapeutics Inc.
- Brett Hagen (SVP, Finance and CAO) received options to purchase 62,273 shares at $10.37 per share, vesting over 4 years.
- Jerad G. Seurer (General Counsel and Corporate Secretary) received options to purchase 93,411 shares at $10.37 per share, vesting over 4 years.
- Fairmount Healthcare Fund II L.P. received 10,555,507 common shares, 4,013 shares of Series A Non-Voting Preferred Stock (convertible into 4,013,000 common shares), and pre-funded warrants for 1,468,222 common shares in the merger.
- The exchange ratio for Pre-Merger Mentari common stock and Series A Preferred Stock was 0.20065 shares of issuer common stock per share.
- Todd Shegog filed a Form 3 but reported no securities owned.
- All filings include Powers of Attorney authorizing officers to execute future Section 16 filings.
Financial Impact
No financial figures disclosed beyond option exercise prices and share counts.
Risk Factors
- Potential dilution from the conversion of Series A Preferred Stock (up to 4,013,000 common shares) and exercise of pre-funded warrants (1,468,222 common shares).
- Beneficial ownership limitation of 19.99% on Fairmount's holdings may affect future conversion/exercise timing.
Investment Themes
Documents Analyzed
This report is based on 15 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (MTRI), Batch item 1 | 0001193125-26-458264 |
| Document: 0001193125-26-458264-index-headers.html | 0001193125-26-458263 |
| Document: 0001193125-26-458264-index.html | 0001193125-26-458262 |
| Document: 0001193125-26-458264.txt | 0001193125-26-458261 |
| 3 Filing (MTRI), Batch item 5 | 0001193125-26-458263 |
| Document: 0001193125-26-458263-index-headers.html | 0001193125-26-458264 |
| Document: 0001193125-26-458263-index.html | 0001193125-26-458264 |
| Document: 0001193125-26-458263.txt | 0001193125-26-458264 |
| 3 Filing (MTRI), Batch item 9 | 0001193125-26-458262 |
| Document: 0001193125-26-458262-index.html | 0001193125-26-458264 |
| Document: 0001193125-26-458262.txt | 0001193125-26-458264 |
| 3 Filing (MTRI), Batch item 12 | 0001193125-26-458261 |
| Document: 0001193125-26-458261-index-headers.html | 0001193125-26-458264 |
| Document: 0001193125-26-458261-index.html | 0001193125-26-458264 |
| Document: 0001193125-26-458261.txt | 0001193125-26-458264 |
Track record
10 reports on MTRI
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $17.90 Now $19.87 −11.01% settles Dec 15
- Nov 16, 2026today 8-K Neutral 6/10 Entry $18.60 Now $19.87 +6.83% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $19.02 Now $19.87 +4.47% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $15.75 Now $19.87 +26.16% settles Dec 15
- Nov 12, 20264d ago SC 13D Neutral 5/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Viewing Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 10, 20266d ago 8-K Mixed 7/10 Entry $15.61 Now $19.87 +27.30% settles Dec 10
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers